الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 73 |  |  |
| | | from | 73 | | |
Abstract
Lung metastases are found in 20-55% of all cancer patients, though prevalence varies according to the type of primary cancer; spread to the lungs is usually a sign of an advanced malignant disease.
Historically, whole lung irradiation has been used for decades in the treatment of pulmonary metastases originating from a variety of primary malignant cell-types especially in those of bone origin whether for prophylactic or palliative intent. Complete remission after low-dose palliative irradiation has been reported.
We recruited Forty patients with pathologically (histologically or cytological) proven diagnosis of a non-hematopoietic malignancy from Alexandria oncology hospitals, between February 2017 and March 2018.
Patient’s age ranged from 22 to 59 years, with most of patients between ages of 50-60 years, the median age was 43.5 years, Distribution of sex in our patient population female patients was male 24 and 16, respectively, the most common primary site was breast 20% followed by ovaries as primary site were 15%. While other diagnoses of soft tissue sarcoma, osteosarcoma, colorectal cancer and renal cell carcinoma came next with a value of 10%, each.
All patients of the studied population reported various degrees of acute side effects of fatigue, nausea, heartburn and vomiting at 92.1% ,57.9 % ,50.0%, and 7.9%, respectively, the performance status of our patients was improved by shifting 87.5% of patients to PS 2 or less in comparison to the pre-treated patient with PS 3 and 4 of 60%.
A dramatic response was achieved by the studied Whole Lung Irradiation regimen (WLI) regarding dyspnea with a statistically significant p value less than 0.001 turning the subjects from the exclusive pretreated grades III and IV into 81.6 % of patients to grades II and less.
Our patient population had a partial response and stable disease with combined percentage of 87.5
The median duration of symptom control was identified at 1.67 months with a mean value of 1.88 months and less than one quarter of the studied population achieved at a post-treatment 2 months’ interval